Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
CMPS · NASDAQ · Pharmaceutical Preparations
Compass Pathways (CMPS) · oqro.io/stocks/CMPS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$9.01−0.11 (−1.21%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
No open-market purchase by an insider of Compass Pathways is on record in SEC filings since 2006.
Since 2022, Compass Pathways insiders reported 0 open-market purchases and 59 sales on Forms 4 and 5.
No open-market sale by an insider of Compass Pathways (CMPS) was filed with the SEC in the last 90 days.
No trade in Compass Pathways (CMPS) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+70.3% (+$3.72) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $5.29 on Nov 13, 2025 to $9.01 on Nov 13, 2026 (+70.3%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 7 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Chesire, X0.
Last 12 months
+70.3%
Market value
$1.28B
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 17.2M shares sold short (12.1% of shares outstanding), −2.6% vs the previous count, 7.7 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net cash
$393M
Debt $51M, cash $444M, at Sep 30, 2026
Net income, last 12 months
−$266M
Operating profit covers interest -35.4x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 3, 2026.
Fund moves
From a 13F filed Nov 13, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
5 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
5 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
2 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in major depressive disorder, treatment resistant depression, ptsd - post traumatic stress disorder. The ones with the nearest registered primary completion date still ahead:
2 trials have a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Against the S&P 500 over the year
Since Nov 11, 2025, CMPS is up 58.1% and the index fund is up 10.4%: 48 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much CMPS moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Insiders of Compass Pathways reported 0 open-market purchases and 59 sales since 2022; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2024 | — | $24.1M51×51 trades |
| 2023 | — | $66K4×4 trades |
| 2022 | — | $244K4×4 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
On the public record for Compass Pathways over the 12 months to Nov 14, 2026: 2 clinical trials.
